Contact Us

Advanced Imaging for Glaucoma

Casey Eye Institute, OHSU

3375 Southwest Terwilliger Boulevard

Portland, OR 97239-4197

montalto@ohsu.edu

Advanced Imaging for Glaucoma (AIG) is a multi-center bioengineering partnership sponsored by the National Eye Institute, one of the National Institutes of Health (NIH).

The goal of this partnership is to develop advanced imaging technologies that can improve the detection and management of glaucoma. Currently-employed advanced imaging devices include optical coherence tomography, scanning laser polarimetry and scanning laser tomography. The imaging technologies will be evaluated in a longitudinal 5-year clinical trial. The study subjects will include patients with normal eyes, patients with glaucoma, and individuals at risk for developing glaucoma.

July 7, 2011

OHSU Clinical Center will be accepting AIGS study subjects as of July 18, 2011!

The coordinating center for the AIG partnership is located at the Oregon Health & Science Unversity (OHSU). There are a total of four centers that will be conducting the AIG clinical study, two basic science and engineering centers that will develop the advanced imaging instruments and conduct laboratory studies on glaucoma and one resource center.

	University of Miami, Bascom Palmer Eye Institute, Miami, Florida
	University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
	University of Southern California, Doheny Eye Institute, Los Angeles, California
	Oregon Health & Science University, Casey Eye Institute, Portland, Oregon

	Oregon Health & Science University, Casey Eye Institute, Portland, Oregon
	Massachusetts Institute of Technology, Department of Electrical Engineering and Computer Science and Research Lab of Electronics, Boston, Massachusetts

Cleveland Clinic Foundation, Cleveland, Ohio

The specific aims of the AIG clinical studies are to:

1. Predict the development of visual field (VF) abnormalities in individuals at risk for developing glaucoma based on anatomic abnormalities detected by advanced imaging;

2. Predict the development of VF abnormalities in individuals at risk for developing glaucoma based on anatomic changes detected between successive advanced imaging tests; and

3. Determine the sensitivity and specificity of a glaucoma diagnosis based on advanced imaging tests.